| Literature DB >> 15582465 |
David Alagille1, Ronald M Baldwin, Bryan L Roth, Jarda T Wroblewski, Ewa Grajkowska, Gilles D Tamagnan.
Abstract
Noncompetitive antagonists of the human metabotropic glutamate receptor subtype 5 (mGluR5) have been implicated as potential therapeutics for the treatment of a variety of nervous system disorders, including pain, anxiety, and drug addiction. To discover novel noncompetitive antagonists to the mGluR5, we initiated an SAR study around the known lead compounds MPEP and M-MPEP. Our results pointed out the critical role of the para position of the two aromatic rings, which leads to inactive products and permitted the discovery of potent mGluR5 antagonists (e.g., 16, 25, 28, 34 IC(50) = 13.5, 11.9, 21, 15 nM, respectively).Entities:
Mesh:
Substances:
Year: 2005 PMID: 15582465 DOI: 10.1016/j.bmc.2004.09.042
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641